A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates

@article{Vogel2020APS,
  title={A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates},
  author={Annette B. Vogel and Isis Kanevsky and Ye Che and Kena A. Swanson and Alexander Muik and Mathias Vormehr and Lena M. Kranz and Kerstin C. Walzer and Stephanie Hein and Alptekin G{\"u}ler and Jakob Loschko and Mohan S. Maddur and Kristin R Tompkins and Journey Cole and Bonny Gaby Lui and Thomas Ziegenhals and Arianne Plaschke and David Eisel and Sarah C. Dany and Stephanie Fesser and Stephanie Erbar and Ferdia Bates and Diana Schneider and Bernadette Jesionek and Bianca S{\"a}nger and Anna Wallisch and Yvonne Feuchter and Hanna Junginger and Stefanie A. Krumm and Andr{\'e} P. Heinen and Petra Adams-Quack and Julia Schlereth and Christoph Kröner and Shannan Hall-Ursone and Kathleen M. Brasky and Matthew C. Griffor and Seungil Han and Joshua A. Lees and Ellene H Mashalidis and Parag V. Sahasrabudhe and Charles Y. Tan and Danka Pavliakova and Guy Singh and Camila R Fontes-Garfias and Michael Pride and Ingrid Scully and Tara Ciolino and Jennifer Obregon and Michal Gazi and Ricardo Carrion and Kendra J. Alfson and Warren Vincent Kalina and Deepak Kaushal and Pei-Yong Shi and Thorsten Klamp and Corinna Rosenbaum and Andreas N. Kuhn and {\"O}zlem T{\"u}reci and Philip R. Dormitzer and Kathrin U. Jansen and Uğur Şahin},
  journal={bioRxiv},
  year={2020}
}
To contain the coronavirus disease 2019 (COVID-19) pandemic, a safe and effective vaccine against the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is urgently needed in quantities sufficient to immunise large populations. In this study, we report the design, preclinical development, immunogenicity and anti-viral protective effect in rhesus macaques of the BNT162b2 vaccine candidate. BNT162b2 contains an LNP-formulated nucleoside-modified mRNA that encodes the spike… 

Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates

Data show that antibodies induced by the AS03-adjuvanted preS dTM vaccine are sufficient to mediate protection against SARS-CoV-2 and support the evaluation of this vaccine in human clinical trials.

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Evidence is provided that CVnCoV represents a potent and safe vaccine candidate against SARS-CoV-2, and hamsters vaccinated with a suboptimal dose of CVn coV leading to breakthrough viral replication exhibited no evidence of vaccine-enhanced disease.

mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents

Preclinical data for clinical candidate CVnCoV, a lipid nanoparticle (LNP) encapsulated non-modified mRNA vaccine that encodes the full length, pre-fusion stabilised SARS-CoV-2 Spike (S) protein is shown, providing evidence that CVn coV represents a potent and safe vaccine candidate against Sars-Cov-2.

A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants

A novel, well-characterized SARS-CoV-2 vaccine candidate based on extracellular vesicles of Salmonella typhimurium that are decorated with the mammalian cell culture-derived Spike receptor-binding domain (RBD) is presented.

mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection

It is demonstrated that CVnCoV induces robust humoral and cellular responses in non-human primates (NHPs) and is protected from challenge infection with SARS-CoV-2, providing strong support for further clinical testing in ongoing phase 2b/3 efficacy studies.

CV2CoV, an enhanced mRNA-based SARS-CoV-2 vaccine candidate, supports higher protein expression and improved immunogenicity in rats

CV2CoV, a second-generation mRNA vaccine developed for enhanced protein expression and immunogenicity, is described, and results underline the value of CV2 coV as next-generation SARS-CoV-2 mRNA vaccine.

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

RFN, adjuvanted with a liposomal-QS21 formulation (ALFQ), elicits humoral and cellular immune responses exceeding those of current vaccines in terms of breadth and potency and protects against high-dose respiratory tract challenge.
...

References

SHOWING 1-10 OF 51 REFERENCES

Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine

The robust RBD-specific antibody, T-cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest multiple beneficial mechanisms with potential to protect against COVID-19.

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Additional safety and immunogenicity data from the US Phase 1 trial supported selection of the BNT162b2 vaccine candidate for Phase 2/3 large-scale safety and efficacy evaluation, currently underway.

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose.

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

It is shown that the patients had strong immune responses against the viral spike protein, a complex that binds to receptors on the host cell, and monoclonal antibodies isolated here are promising candidates for COVID-19 treatment and prevention.

Middle East respiratory coronavirus (MERS-CoV) spike (S) protein vesicular stomatitis virus pseudoparticle neutralization assays offer a reliable alternative to the conventional neutralization assay in human seroepidemiological studies

The results suggest that the VSV-MERS- CoV-S pseudotype neutralization assay offers a highly specific, sensitive and safer alternative method to detect MERS-CoV neutralizing antibodies in human sera.

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

An engineering strategy for stabilization of soluble S proteins in the prefusion conformation is described, which results in greatly increased expression, conformational homogeneity, and elicitation of potent antibody responses, and an engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV.
...